Telix and Xiel Sign U.K. and Ireland Distribution Agreement for Illuccix®
- Written by PR Newswire Asia - Daily Bulletin Au RSS
MELBOURNE, Australia and LIÈGE, Belgium, March 29, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has signed an exclusive agreement with Xiel Limited (Xiel) for the distribution of Telix's prostate cancer investigational imaging product, Illuccix® (TLX591-CDx, Kit for the...
Read more: Telix and Xiel Sign U.K. and Ireland Distribution Agreement for Illuccix®